BR100 Increased By (0.2%)
BR30 Increased By (0.41%)
KSE100 Increased By (0.07%)
KSE30 Increased By (0.23%)
AGHA 7.75 Decreased By ▼ -0.17 (-2.15%)
BECO 5.19 Decreased By ▼ -0.01 (-0.19%)
BML 58.66 Decreased By ▼ -0.59 (-1%)
BOP 33.69 Increased By ▲ 0.01 (0.03%)
CNERGY 10.61 Increased By ▲ 0.80 (8.15%)
CSIL 5.30 Decreased By ▼ -0.12 (-2.21%)
FCCL 53.74 Increased By ▲ 0.22 (0.41%)
FFL 16.46 Decreased By ▼ -0.22 (-1.32%)
FNEL 1.22 Increased By ▲ 0.01 (0.83%)
KEL 7.28 Decreased By ▼ -0.07 (-0.95%)
KOSM 5.64 Increased By ▲ 0.03 (0.53%)
LOTCHEM 29.65 Increased By ▲ 0.54 (1.86%)
MLCF 96.36 Increased By ▲ 0.86 (0.9%)
NBP 203.53 Decreased By ▼ -0.82 (-0.4%)
NCPL 56.85 Decreased By ▼ -1.39 (-2.39%)
NPL 67.31 Decreased By ▼ -0.48 (-0.71%)
OGDC 318.22 Increased By ▲ 0.28 (0.09%)
PACE 10.63 Decreased By ▼ -0.08 (-0.75%)
PAEL 41.77 Decreased By ▼ -0.06 (-0.14%)
PIBTL 16.81 Increased By ▲ 0.31 (1.88%)
PPL 220.17 Increased By ▲ 0.43 (0.2%)
PRL 49.05 Increased By ▲ 4.46 (10%)
PTC 70.01 Decreased By ▼ -0.76 (-1.07%)
SSGC 29.14 Increased By ▲ 0.21 (0.73%)
TBL 9.77 Decreased By ▼ -0.07 (-0.71%)
TELE 8.82 Increased By ▲ 0.06 (0.68%)
TPL 17.17 Increased By ▲ 0.72 (4.38%)
TPLP 12.51 Increased By ▲ 0.41 (3.39%)
TREET 22.59 Decreased By ▼ -0.21 (-0.92%)
TRG 60.22 Increased By ▲ 0.19 (0.32%)
By

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed for this article.